Vaccinex, Inc. Made Headway

Vaccinex, Inc. (VCNX:NASDAQ) shot up at $1.94, a gain of 24.4%. The stock appeared on our News Catalysts scanner on Fri, Jan 28, 2022 at 11:17 AM in the 'BIOTECH' category. From Thu, Jan 27, 2022, the stock recorded 66.67% Up Days and 70.00% Green Days

About Vaccinex, Inc. (VCNX:NASDAQ)

Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its lead product candidate VX15 is in clinical development for the treatment of NSCLC, osteosarcoma and Huntington's disease and additional product candidates VX5 and VX25 are in earlier stages of development.